Erratum: The Effect of <b><i>IGF2BP2</i></b> Gene Polymorphisms on Pioglitazone Response in Chinese Type 2 Diabetes Patients

<b><i>Background:</i></b> Genome-wide association studies identified that insulin-like growth factor 2 mRNA-binding protein 2 <i>(IGF2BP2)</i> genetic polymorphisms are related to type 2 diabetes mellitus (T2DM) in several populations. This study aimed to investigate whether the <i>IGF2BP2</i> gene rs1470579 and rs4402960 polymorphisms were associated with T2DM and pioglitazone efficacy in Chinese T2DM patients. <b><i>Methods:</i></b> A total of 281 T2DM patients and 111 healthy volunteers were enrolled to identify the <i>IGF2BP2</i> gene rs1470579 and rs4402960 polymorphisms; 86 patients were randomly selected and given a 12-week pioglitazone treatment (30 mg/day). Fasting plasma glucose, postprandial plasma glucose (PPG), glycated hemoglobin, serum triglycerides (TG), total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (HDL-C) were determined before and after pioglitazone treatment. <b><i>Results:</i></b> The results showed that the <i>IGF2BP2</i> gene rs1470579 and rs4402960 polymorphisms were associated with T2DM in a Chinese population (OR = 2.002, 95% CI 1.170-3.426, p < 0.05; OR = 1.879, 95% CI 1.110-3.182, p < 0.05). The effect of pioglitazone on PPG (p < 0.05), TG (p < 0.01) and HDL-C (p < 0.05) was lower in patients with the rs1470579 AC+CC genotypes than in AA genotype carriers. Its effect on PPG level was also lower in patients with the GT+TT genotypes of rs4402960 than in patients with the GG genotype (p < 0.05). <b><i>Conclusions:</i></b> The <i>IGF2BP2</i> gene rs1470579 and rs4402960 polymorphisms were associated with T2DM and therapeutic efficacy of pioglitazone in this Chinese population. i 2014 S. Karger AG, Basel